New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ADBE;ALXA;BBY;BV;ZQK;CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
11:55 EDTCYTXCytori Therapeutics management to meet with Roth Capital
Subscribe for More Information
January 22, 2015
11:27 EDTCYTXCytori Therapeutics management to meet with Roth Capital
Subscribe for More Information
10:35 EDTBBYOptions with decreasing implied volatility
Options with decreasing implied volatility: CZR ACHN NFLX SN NBR TLM CREE BBY LNCO BBRY
09:11 EDTALXAAlexza Pharmaceuticals initiates Phase 2a study of AZ-002 in epilepsy
Alexza Pharmaceuticals has initiated a Phase 2a study of AZ-002 - Staccato alprazolam -, which is being developed for the management of epilepsy in patients with acute repetitive seizures. ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs. Alexza expects to announce results from this study in 1H15.
09:11 EDTALXAAlexza Pharmaceuticals initiates Phase 2a study of AZ-002 in epilepsy
Subscribe for More Information
January 21, 2015
12:12 EDTBBYBest Buy, home retailers seen getting biggest bump from Sears demise
Subscribe for More Information
10:47 EDTBBYOptions with decreasing implied volatility
Subscribe for More Information
10:01 EDTBVOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ashford Hospitality (AHT) upgraded to Outperform from Neutral at Credit Suisse... BAE Systems (BAESY) upgraded to Buy from Neutral at Goldman... Bazaarvoice (BV) upgraded to Outperform from Market Perform at Cowen... Becton Dickinson (BDX) upgraded to Outperform at Cowen... CVS Health (CVS) upgraded to Buy from Neutral at Goldman... Camden Property (CPT) upgraded to Outperform from Neutral at Credit Suisse... ConocoPhillips (COP) upgraded to Buy from Neutral at BofA/Merrill... Cornerstone OnDemand (CSOD) upgraded to Buy from Neutral at DA Davidson... Cree (CREE) upgraded to Overweight at Stephens... DDR Corp. (DDR) upgraded to Outperform from Neutral at Credit Suisse... EastGroup Properties (EGP) upgraded to Outperform from Neutral at Credit Suisse... Energy Transfer Partners (ETP) upgraded to Outperform from Neutral at Credit Suisse... Esperion (ESPR) upgraded at BofA/Merrill... Exxon Mobil (XOM) upgraded to Outperform from Market Perform at Wells Fargo... FXCM (FXCM) upgraded to Market Perform from Underperform at Keefe Bruyette... Fair Isaac (FICO) upgraded to Overweight from Equal Weight at Barclays... Golar LNG (GLNG) upgraded to Buy from Hold at Nordea... Gran Tierra (GTE) upgraded to Buy at Canaccord... Host Hotels (HST) upgraded to Outperform from Neutral at Credit Suisse... J.M. Smucker (SJM) upgraded to Overweight from Neutral at JPMorgan... Kilroy Realty (KRC) upgraded to Neutral from Underperform at Credit Suisse... Level 3 (LVLT) upgraded to Outperform from Market Perform at Wells Fargo... Lowe's (LOW) upgraded to Overweight from Equal Weight at Morgan Stanley... Michael Kors (KORS) upgraded to Outperform at Cowen... Netflix (NFLX) upgraded at Nomura... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ruckus Wireless (RKUS) upgraded to Outperform from Market Perform at Northland... Santander Mexico (BSMX) upgraded to Neutral from Underperform at Credit Suisse... Scorpio Tankers (STNG) upgraded to Buy at Canaccord... Sprouts Farmers Markets (SFM) upgraded to Buy from Neutral at BofA/Merrill... Strategic Hotels (BEE) upgraded to Outperform from Neutral at Credit Suisse... The Medicines Co. (MDCO) upgraded to Outperform from Market Perform at Leerink... Whole Foods (WFM) upgraded at Sterne Agee... Wolseley (WOSYY) upgraded to Neutral from Underperform at Exane BNP Paribas.
09:55 EDTBVBazaarvoice upgraded at Morgan Stanley
Pre-open, Morgan Stanley upgraded Bazaarvoice to Overweight from Equal Weight with a $10 price target. The firm upgraded shares based on improved execution, accelerating growth, the Department of Justice resolution, and valuation.
January 20, 2015
16:25 EDTCYTXCytori says STAR trial will begin enrolling in 2015
Subscribe for More Information
10:20 EDTBBYOptions with decreasing implied volatility
Options with decreasing implied volatility: RPRX TLM BBY GME CBST NPSP
08:40 EDTCYTXCytori Therapeutics price target raised to $6 from $3.50 at Roth Capital
Roth Capital increased its price target on Cytori after the company received final FDA approval for a clinical trial of its treatment for scleroderma., and the firm attended an event hosted by the company with a scleroderma expert. Roth says that the expert highlighted the unmet medical need in scleroderma as well its significant morbidity and mortality. The firm expects the company's visibility to improve this year, and it keeps a Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use